Origo Biopharma participates at BIO-Europe® Digital

Origo Biopharma will attend the international partnering conference BIO-Europe Digital on October 26–29, 2020.

The company will present its “organ restricted ALK 5 inhibitors for the treatment of Crohn´s disease and idiopathic pulmonary fibrosis” programs. The unique features of the programs: high compound concentration in target organ to maximize efficacy in fibrotic conditions, minimal exposure in plasma to minimize side effects, will pave the way for possible future collaborations.
The company´s participation is financially supported by Igape, Xunta de Galicia, and the European Union.